Trial
NCT01121588
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Pfizer
Collaborators
—
Condition
Neoplasms Malignant
Intervention
Crizotinib
Why stopped
Termination of further treatment on the study due to the availability of commercial supply or a rollover study (NCT05160922) that will allow active subjects to continue receiving treatment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-23